SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively trending due to breaking news of a Department of Justice criminal probe into Fed Chair Jerome Powell, which the community widely perceives as unprecedented political pressure on the central bank. This development is sparking intense debate among investors about the Federal Reserve's independence and its potential impact on future monetary policy, raising concerns about market stability and the dollar's credibility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following its CES 2026 showcase, where it unveiled significant advancements in agentic voice and visual AI, including new partnerships with TomTom for multi-agent navigation and Richtech Robotics for automated food systems. The community is actively discussing these innovative applications in automotive and robotics, fueled by ongoing speculation about a potential short squeeze due to the stock's high short interest. Investors are keenly watching SOUN's position in the expanding AI market, highlighting its unique white-label solutions as a competitive advantage.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is currently trending due to heightened competitive pressures in the weight-loss market, specifically Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 at competitive prices, a product HIMS currently lacks. This news, compounded by a recent analyst downgrade, has driven significant bearish sentiment and a notable price correction. However, a segment of the community views the dip as an oversold opportunity, emphasizing HIMS' long-term strategy in personalized healthcare, proprietary compounding labs, and international expansion beyond just weight-loss treatments.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing extreme volatility following news of a new manufacturing partnership and a $10 million private placement, sparking intense debate between its operational progress and immediate dilution concerns. Community discussion centers on the potential for a massive short squeeze, with many comparing it to previous low-float runners, while others caution about dilution from the recent offering and the stock's significant price fluctuations.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum after announcing a record total contract value exceeding $1.1 billion for 2025, fueled by data agreements with over 70 pharmaceutical and biotech companies. This major business development highlights the strength of its AI-driven precision medicine platform, sparking widespread community excitement and further institutional interest in its role in advancing drug discovery and development.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending following strong preliminary financial results that anticipate beating revenue guidance and an expanded partnership with Bio-Rad Laboratories to develop high-complexity cancer diagnostic assays. This positive news, coupled with significant insider buying, has fueled a surge in interest and bullish sentiment. However, community discussions are polarized, with some celebrating growth and strategic advancements, while others remain cautious due to a recent reverse stock split and ongoing concerns about cash burn.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to intensifying speculation surrounding a potential multi-billion dollar takeover, with Eli Lilly frequently rumored as an interested suitor. The community is actively discussing the significant upside driven by its compelling Phase 3 data for its ulcerative colitis treatment, obefazimod, which positions it as a highly attractive asset in the competitive inflammatory bowel disease market. Recent reports from French officials confirming interest from multiple pharmaceutical companies are further fueling the robust buyout conversation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as news circulates about a federal investigation into the Federal Reserve Chair, which is widely seen by the community as political pressure potentially undermining the central bank's independence. This has ignited debate among investors regarding its potential market impact on tech and growth stocks, though a "buy the dip" mentality is also evident.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics ($ATRA) is experiencing a significant downturn and intense community discussion after receiving a Complete Response Letter (CRL) from the FDA for its EBVALLO BLA, citing issues solely related to a third-party manufacturing facility rather than the drug's clinical efficacy or safety. While many express frustration over the unexpected delay and potential for dilution, a substantial portion of the community views this as an "overreaction" and a strategic buying opportunity, given the drug's existing approval in Europe and the high unmet medical need. Attention is now focused on the timeline for resolving manufacturing concerns, potential resubmission, and the company's exploration of strategic alternatives, including a possible acquisition by its partner, Pierre Fabre.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is a top trending stock, driven by its strategic transfer to the Nasdaq exchange which reinforces its image as a tech-enabled e-commerce innovator. The company's recent AI partnership with Google for shopping experiences and strong performance throughout the holiday shopping period are fueling robust community discussion and multiple analyst upgrades. Investors are keenly watching its valuation as it leverages technology for continued growth in the competitive retail landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
